Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2009-10-16

Clinical Trial Update: Evaluating Aranesp® in Subjects With End Stage Renal Disease onChronic Hemodialysis [Phase 4]

View source ↗

Summary

Phase 4 clinical trial evaluating Aranesp (darbepoetin alfa) in subjects with end-stage renal disease on chronic hemodialysis has been completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • ARANESP (DARBEPOETIN ALFA)

Snippet

Sponsor: Amgen | Conditions: End Stage Renal Disease | Phase 4 | Status: COMPLETED